We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic
News

Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic

Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic
News

Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Thanks to the joint efforts of the research teams of the two companies, a ‘first-in-class’ compound with an original mechanism of action for the treatment of cardiometabolic disorders is today entering clinical trials.

Jean-François Mouney, Chairman of GENFIT’s Management Board, declared: “We are very pleased to see a molecule originating from one of our research partnerships successfully achieve an important phase in its development. This provides strong recognition by the pharmaceutical industry of our scientific expertise and of the relevance of our research targets. This is the second program to enter clinical trials from this strategic collaboration initiated 8 years ago. This new achievement underlines the talent of our research teams, as well as those of our partner. We are confident that our innovative and collaborative approach will provide an efficient therapeutic strategy for cardiometabolic diseases and associated causes of mortality and morbidity.”

In addition to this initial milestone, GENFIT will potentially receive further clinical development-based milestone payments, as well as royalties on future sales.
Advertisement